Skip to main content
devices header

The UnoReady® and Sensoready® pens are designed to help patients inject comfortably and confidently1,2

UnoReady® and Sensoready® at a glance

devices chart 10
#Usability of the autoinjector in the JUNCTURE study was determined by observer rating of successful, hazard-free self-injection and subject rating of autoinjector acceptability. Successful self-administration was defined as subject successfully performing critical steps as per the Instructions for Use. All evaluable subjects (N=178) successfully self-administered treatment at Week 1. Ease of use was also evaluated using the SIAQ at Week 12. Scores for the entire cohort ranged from 8.95 to 9.28, indicating excellent subject-reported autoinjector ease of use.4
**Adults only.

*Limitations apply. Enrolled patients awaiting coverage for COSENTYX after 2 years may be eligible for a limited Program extension. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

HS, hidradenitis suppurativa; IGA mod 2011, Investigator’s Global Assessment modified 2011; PASI, Psoriasis Area and Severity Index; PsO, plaque psoriasis; SIAQ, Self-injection Assessment Questionnaire.

1. Data on file. CAIN457A2325 Clinical Study Report. Novartis Pharmaceuticals Corp; August 2020.
2. Nash P, Mease PJ, McInnes IB, et al; on behalf of the FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.
3. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
4. Paul C, Lacour J-P, Tedremets L, et al; for the JUNCTURE Study Group. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082-1090.
5. Data on file. AIN457A Summary of Clinical Safety. Novartis Pharmaceuticals Corp; October 2013.